CD192 Gene Variant and Susceptibility to Cervical Cancer: a Meta Analysis

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Aug 27

PMID 26309594

Authors

Yuying Chen

Xinli Liu

Min Chen

Jian Shen

Yanqi Lu

Lei Yu

Shouying Liu

Affiliations

Soon will be listed here.

Abstract

Background: Several molecular epidemiological studies have explored the association between G46295A variant of CD192 gene and cervical cancer susceptibility in distinct populations. However, the results are contradictory. To provide convincing evidence for the association, we performed the present meta-analysis incorporating all case-control studies.

Methods And Findings: The Cochrane, Google Scholar and PubMed databases were systematically searched to identify the potentially relevant studies. Statistical analyses were performed using R software. Crude odds ratio (OR) was calculated to estimate the risk of cervical cancer. Five case-control studies were considered in the final analysis. Using the homozygous, heterogeneous, allele, dominant, and recessive model, we found the association between CD192 G46295A variant and cervical cancer was not statistically significant.

Conclusions: This meta-analysis shows that the CD192 G46295A variant may not confer genetic susceptibility towards cervical cancer.

References

Coelho A, Matos A, Catarino R, Pinto D, Pereira D, Lopes C . Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol. 2005; 96(3):760-4. DOI: 10.1016/j.ygyno.2004.11.028. View

Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L . The origin and function of tumor-associated macrophages. Immunol Today. 1992; 13(7):265-70. DOI: 10.1016/0167-5699(92)90008-U. View

Vicari A, Caux C . Chemokines in cancer. Cytokine Growth Factor Rev. 2002; 13(2):143-54. DOI: 10.1016/s1359-6101(01)00033-8. View

Garred P . Chemokine-receptor polymorphisms: clarity or confusion for HIV-1 prognosis?. Lancet. 1998; 351(9095):2-3. DOI: 10.1016/S0140-6736(98)22001-0. View

Karnoub A, Weinberg R . Chemokine networks and breast cancer metastasis. Breast Dis. 2007; 26:75-85. DOI: 10.3233/bd-2007-26107. View

Levina V, Nolen B, Marrangoni A, Cheng P, Marks J, Szczepanski M . Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res. 2009; 15(8):2647-56. PMC: 2669845. DOI: 10.1158/1078-0432.CCR-08-2024. View

Zheng B, Wiklund F, Gharizadeh B, Sadat M, Gambelunghe G, Hallmans G . Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res. 2006; 26(5B):3669-74. View

Polentarutti N, Allavena P, Bianchi G, Giardina G, Basile A, Sozzani S . IL-2-regulated expression of the monocyte chemotactic protein-1 receptor (CCR2) in human NK cells: characterization of a predominant 3.4-kilobase transcript containing CCR2B and CCR2A sequences. J Immunol. 1997; 158(6):2689-94. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

10.

Sica A, Saccani A, Bottazzi B, Bernasconi S, Allavena P, Gaetano B . Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol. 2000; 164(2):733-8. DOI: 10.4049/jimmunol.164.2.733. View

11.

Narter K, Agachan B, Sozen S, Cincin Z, Isbir T . CCR2-64I is a risk factor for development of bladder cancer. Genet Mol Res. 2010; 9(2):685-92. DOI: 10.4238/vol9-2gmr829. View

12.

Zafiropoulos A, Crikas N, Passam A, Spandidos D . Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet. 2004; 41(5):e59. PMC: 1735773. DOI: 10.1136/jmg.2003.013649. View

13.

Smith M, Dean M, Carrington M, Winkler C, Huttley G, Lomb D . Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City.... Science. 1997; 277(5328):959-65. DOI: 10.1126/science.277.5328.959. View

14.

Dambach D, Watson L, Gray K, Durham S, Laskin D . Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. Hepatology. 2002; 35(5):1093-103. DOI: 10.1053/jhep.2002.33162. View

15.

Pease J, Williams T . The attraction of chemokines as a target for specific anti-inflammatory therapy. Br J Pharmacol. 2006; 147 Suppl 1:S212-21. PMC: 1760746. DOI: 10.1038/sj.bjp.0706475. View

16.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

17.

Charo I, Myers S, Herman A, Franci C, Connolly A, Coughlin S . Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci U S A. 1994; 91(7):2752-6. PMC: 43448. DOI: 10.1073/pnas.91.7.2752. View

18.

Chatterjee K, Dandara C, Hoffman M, Williamson A . CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer. 2010; 10:278. PMC: 2893113. DOI: 10.1186/1471-2407-10-278. View

19.

Oppenheim J, Zachariae C, Mukaida N, Matsushima K . Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol. 1991; 9:617-48. DOI: 10.1146/annurev.iy.09.040191.003153. View

20.

Michael N, Louie L, Rohrbaugh A, Schultz K, Dayhoff D, Wang C . The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med. 1997; 3(10):1160-2. DOI: 10.1038/nm1097-1160. View